How post-authorization monitoring works, what the data shows, and how to read VAERS properly.
THIS PAGE IS NOT MEDICAL ADVICE
This page is a factual reference on how vaccine safety is monitored and where the data lives. It does not recommend for or against any vaccine. Anyone weighing a medical choice should consult a clinician who knows their history. If a specific reaction is the reason for reading this, seek medical care first, then consider filing a report at vaers.hhs.gov/reportevent.html.
COVID-19 vaccines went through what CDC and FDA describe as the most extensive post-authorization safety monitoring in U.S. history. The data those systems produced is public, and so are the limitations of each system. This page explains which systems collect what, what VAERS numbers represent, which rare adverse events have been documented at real incidence rates, and where the peer-reviewed evidence lives. Every claim links to a primary source.

The short version
- Vaccine safety after authorization is monitored through multiple overlapping systems, not one. VAERS is just the public-facing signal detector.
- A report to VAERS does not mean the vaccine caused the event. VAERS accepts reports from anyone and is a signal-generating system, not a causal record.
- Several rare adverse events have been officially documented at per-million-dose rates: myocarditis and pericarditis (mRNA, concentrated in young males), anaphylaxis, and GBS (J&J/Janssen only).
- How those small per-dose rates compare to the same events following COVID infection itself is a separate calculation, and it lives in the peer-reviewed literature, not in raw VAERS totals.
How COVID-19 vaccine safety is monitored
The U.S. runs five main systems in parallel. They are complementary by design: the weaknesses of each are covered by another.
- VAERS (co-managed by CDC and FDA since 1990). Passive surveillance. Anyone can file a report. Its job is to flag possible signals for investigation, not to prove causation. vaers.hhs.gov.
- V-safe (CDC, launched December 13, 2020). An active smartphone check-in tool; enrollees get texts asking how they feel over days, weeks, and months. Over 10 million people registered and more than 151 million surveys had been completed as of 2025.
- VSD (Vaccine Safety Datalink). CDC partnership with nine healthcare organizations that reviews electronic health records to compare event rates in vaccinated vs. unvaccinated populations – the tool capable of estimating causation.
- BEST (Biologics Effectiveness and Safety System, FDA). Active surveillance across claims data and EHRs.
- CISA (Clinical Immunization Safety Assessment Project). Clinical consultations and targeted research on specific safety questions.
Outside the U.S., the equivalent roles are played by the European Medicines Agency (EMA, which runs EudraVigilance) and the Public Health Agency of Canada. The Global Vaccine Data Network (GVDN) aggregates active surveillance across multiple countries.
What VAERS actually shows – and what it doesn’t
VAERS is the most frequently misunderstood piece of the system. The HHS page for VAERS states the limitation plainly in its own disclaimer: the number of reports alone cannot be read as evidence of causation, or as evidence of the actual frequency or severity of a vaccine problem. Reports can be incomplete, inaccurate, coincidental, or unverified.
A VAERS record shows that a health event happened some time after vaccination. That’s all. Anyone can file (patients, family members, lawyers, strangers), no verification is required, and because tens of millions receive vaccines in any given year, a background rate of heart attacks, strokes, cancer diagnoses, and deaths will appear in the reports as pure coincidence. Separating signal from noise is the job of VSD, BEST, EMA studies, and the published literature, not raw VAERS counts. Claims that treat those totals as a proven vaccine death toll misread what the system is designed to capture.
On May 8, 2025, CDC and FDA expanded VAERS public data to include secondary (follow-up) reports on the same events. That increased the apparent report count without representing new events, documented at vaers.hhs.gov/data/dataguide.html.
Documented rare adverse events
Monitoring systems have confirmed a small number of rare adverse events after COVID-19 vaccination, with incidence rates estimated from active surveillance and peer-reviewed studies:
- Myocarditis and pericarditis after mRNA vaccines. Highest risk: adolescent and young-adult males, 2–7 days after a second dose. Per the updated FDA label (2025), unadjusted incidence for the 2023–2024 formula was about 8 cases per million doses in ages 6 months–64, rising to about 27 per million in males aged 12–24. Most reported cases resolve with rest and standard care; longer-term follow-up studies found no vaccine-associated cardiac deaths or heart transplants.
- Anaphylaxis. About 5 confirmed cases per million doses of the original monovalent mRNA series (VSD data, Moderna and Pfizer within the same range). Treatable on-site with epinephrine.
- Guillain-Barré syndrome (GBS). Elevated in the 21 days after the Johnson & Johnson/Janssen (adenoviral-vector) vaccine – the VSD estimated the rate was about 21 times higher than after mRNA vaccines in the same window. This was one reason the J&J/Janssen vaccine was discontinued in the U.S. in 2023.
- Thrombosis with thrombocytopenia syndrome (TTS). A very rare clotting disorder identified after the J&J/Janssen vaccine; also part of the reason for that vaccine’s discontinuation.
For context: a CDC-affiliated analysis found that SARS-CoV-2 infection itself raised the risk of myocarditis to about 146 cases per 100,000 infections, roughly 16 times background. That comparison, not raw VAERS totals, is what clinicians and regulators use when weighing risks and benefits.
Where the peer-reviewed record lives
- CDC’s ACIP GRADE reviews grade the certainty of each finding. The 2023–2024 and 2024–2025 COVID-19 GRADE documents are on the CDC ACIP site.
- National Academies of Sciences, Engineering, and Medicine published a comprehensive review of CDC’s COVID-19 vaccine safety research program on October 7, 2025.
- Faksova et al. 2024 (Vaccine) pooled data from 99 million people across the GVDN network. Semenzato et al. 2024 (JAMA) followed long-term outcomes of vaccine-associated vs. infection-associated myocarditis.

What changed in 2025–2026
U.S. vaccine policy shifted significantly after Robert F. Kennedy Jr. became HHS Secretary in February 2025. This page tracks what changed without taking a position on the merits.
- June 9, 2025: HHS removed all 17 members of CDC’s Advisory Committee on Immunization Practices (ACIP) and replaced them with seven new members, several of whom had publicly questioned vaccine safety consensus. The AMA passed an emergency resolution calling for a Senate investigation.
- Mid-2025: CDC withdrew universal COVID-19 vaccine recommendations for children and pregnant people. Six major medical societies filed suit against HHS over the rollback.
- August 2025: HHS wound down federally funded mRNA vaccine development, canceling roughly $500 million in mRNA R&D projects.
- January 2026: CDC cut the universal childhood immunization schedule from 17 to 11 diseases. Measles, polio, and pertussis remain universally recommended; COVID-19, RSV, rotavirus, hepatitis A, flu, and meningococcal moved to specific populations or after-consultation status.
- March–April 2026: A federal judge ruled the reconstituted ACIP lacked sufficient vaccine expertise. HHS rewrote the ACIP charter in April 2026, adding vaccine-skeptical groups as non-voting liaisons.
What did not change: VAERS, V-safe, VSD, BEST, EMA, and PHAC continue to operate, and the peer-reviewed record through 2024 remains the technical baseline.
Talking to a clinician
For any personal medical question, a clinician with access to the patient’s history is in a much better position than a web page. Bring specifics: conditions, current medications, prior vaccine reactions, pregnancy status if relevant. If a specific symptom or reaction is the reason for reading this, seek medical care first, then consider filing a VAERS report. The Countermeasures Injury Compensation Program (CICP) covers COVID-19 vaccines; the broader Vaccine Injury Compensation Program (VICP) covers most routinely administered vaccines.
Questions people ask
That reports were filed following vaccination. It does not prove the vaccine caused any event. HHS states this directly on the VAERS page. Confirmed incidence rates come from active surveillance systems (VSD, BEST) and peer-reviewed studies.
The opposite. CDC and FDA built a new active-surveillance tool (V-safe) specifically for COVID-19, expanded existing systems, and required manufacturers to conduct post-approval studies. The National Academies’ October 2025 review catalogued dozens of peer-reviewed safety studies produced during the monitoring period.
Myocarditis and pericarditis (mRNA vaccines, concentrated in young males, about 8–27 cases per million doses depending on age and sex); anaphylaxis (about 5 cases per million doses, treatable on-site); and GBS/TTS (both elevated after J&J/Janssen, no longer in U.S. use).
Yes. Universal recommendations for children and pregnant people were withdrawn in 2025, and the childhood schedule was reduced in January 2026. COVID-19 vaccines are now recommended for specific populations or after consultation with a clinician. Coverage status varies by insurer and state.
Online at vaers.hhs.gov/reportevent.html, or by calling 1-800-822-7967. V-safe participants can be prompted to file through the app. Healthcare providers are legally required to report certain events.
No regulatory agency in the US, Canada, or the EU has approved ivermectin for COVID-19. The NIH COVID-19 Treatment Guidelines Panel recommends against its use for this purpose. A 2023 Cochrane systematic review of 11 randomised trials found no significant reduction in mortality, hospitalization, or symptom duration compared with placebo. High-profile anecdotal reports from athletes or public figures describe subjective improvement; anecdotal recovery is not equivalent to controlled evidence. Clinicians can prescribe off-label, but the peer-reviewed evidence does not support efficacy for COVID-19.
A NOTE ON SOURCING
Every claim on this page is traceable to a CDC, FDA, HHS, EMA, or PHAC page, an FDA-approved product label, a peer-reviewed study, or an official committee record. Where U.S. policy shifted in 2025–2026, the change is dated and attributed. Corrections: send the page URL, the specific sentence, and a primary source via the contact method in the site footer.
This page is informational only. It is not affiliated with any government, medical, or institutional body, has no connection to content formerly hosted on this domain, and should not be treated as medical advice. For personal health decisions, consult a licensed clinician.
